EGFR and non-small cell lung carcinoma: As knowledge of tumor biology continues to grow, it becomes increasingly apparent that alterations often work in concert to affect pathway regulation and therapeutic efficacy highlighting the need for new targeted therapies and combination therapies that target multiple alterations simultaneously.2,4–7 For example, in lung cancer, the notion of the single driver alteration has been dispelled by studies demonstrating multiple co-occurring driver alterations in patients with EGFR-mutant non-small cell lung cancer, including mutations in PIK3CA or CTNNB1.8–10